1. Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroo- phthalmol. 2008; 28:265–8.
Article
2. Sivakumaran P, Harrison AC, Marschner J, Martin P. Ocular toxicity from ethambutol: a review of four cases and recommended precautions. N Z Med J. 1998; 111:428–30.
3. Chatterjee VK, Buchanan DR, Friedmann AI, Green M. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest. 1986; 80:288–91.
Article
4. Schild HS, Fox BC. Rapid-onset reversible ocular toxicity from ethambutol therapy. Am J Med. 1991; 90:404–6.
Article
5. Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther. 1997; 13:473–7.
Article
6. Kumar A, Sandramouli S, Verma L, et al. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol. 1993; 13:15–7.
7. Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with etham-butol-induced optic neuropathy. Br J Ophthalmol. 2007; 91:895–7.
Article
8. Zoumalan CI, Agarwal M, Sadun AA. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2005; 243:410–6.
Article
9. Yen MY, Wang AG, Chiang SC, Liu JH. Ethambutol retinal toxicity: an electrophysiologic study. J Formos Med Assoc. 2000; 99:630–4.
10. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol. 2009; 93:1251–4.
Article
11. Sihota R, Sony P, Gupta V, et al. Diagnostic capability of optical coherence tomography in evaluating the degree of glaucomatous retinal nerve fiber damage. Invest Ophthalmol Vis Sci. 2006; 47:2006–10.
Article
12. Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int. 2002; 40:573–84.
Article
13. Sadun A. Acquired mitochondrial impairment as a cause of optic nerve disease. Trans Am Ophthalmol Soc. 1998; 96:881–923.
14. Sadun AA. Mitochondrial optic neuropathies. J Neurol Neurosurg Psychiatry. 2002; 72:423–5.
15. Saadati HG, Hsu HY, Heller KB, Sadun AA. A histopathologic and morphometric differentiation of nerves in optic nerve hypoplasia and Leber hereditary optic neuropathy. Arch Ophthalmol. 1998; 116:911–6.
Article
16. Sadun AA, Carelli V, Salomao SR, et al. Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol. 2003; 136:231–8.
Article
17. Sadun AA, Win PH, Ross-Cisneros FN, et al. Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve. Trans Am Ophthalmol Soc. 2000; 98:223–32.
18. Yoon YH, Jung KH, Sadun AA, et al. Ethambutol-induced vacuo-lar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol. 2000; 162:107–14.
Article
19. Jin YH. Optic Neuropathy induced by Ethambutol and Vitamine B12 Effect against Ethambutol. Korean Ophthalmol Soc. 1983; 24:857–63.
20. Lee EJ, Kim SJ, Choung HK, et al. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol. 2008; 28:269–77.
Article